EUCTR2005-000993-29-IT
Active, not recruiting
Not Applicable
A prospective, randomized, investigator-blind, controlled, clinical study of phase III on the clinical efficacy and tolerability of hMG-IBSA IBSA Institut Biochimique sa versus Menopur Ferring administered subcutaneously in women undergoing controlled ovarian hyperstimulation COH in an ART programme IVF .
DrugsMenopur
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- IBSA
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study to assess the safety, pharmacokinetics (the way thebody absorbs, distributes and eliminates the drug) and pharmacodynamics (effects of drug on the body) of UCB4940 in patients with psoriasis.EUCTR2012-002086-35-GBCB Celltech39
Active, not recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisBronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2019-002840-26-GBovartis Pharma AG72
Active, not recruiting
Phase 1
Study of LIK066 in overweight and obese women with polycystic ovary syndromepolycystic ovary syndromeMedDRA version: 20.0Level: LLTClassification code 10036050Term: Polycystic ovarySystem Organ Class: 100000004872Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]EUCTR2017-001373-16-DEovartis Pharma AG29
Active, not recruiting
Phase 1
Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisBronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2019-002840-26-DEovartis Pharma AG72
Active, not recruiting
Phase 1
Study to assess the efficacy and safety of CJM112 in patients with inadequately controlled severe asthmaInadequately controlled moderate to severe asthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2017-000205-21-DKovartis Pharma AG110